Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
The effects of chemotherapy, with nitrosoureas or dimethyl-triazeno-imidazole-carboxamide (DTIC), or immunotherapy with Bacillus Calmette-Guérin (BCG), on cell-mediated immunity (CMI), and serum blocking factor (BF) to melanoma cells were studied in 23 patients. Studies were performed with autologous or allogenic melanoma target cells obtained from recent biopsy, in 16 mm diameter plastic wells. Assays for lymphocyte-mediated cytotoxicity and BF were performed at weekly intervals over the course of 3-4 mo, with some studies extending beyond 3 yr. The specificity of cytotoxicity was good with these methods. Nine patients given nitrosoureas, predominantly methyl-chloroethyl-cyclohexyl-nitrosourea, showed a transient decline in CMI from 42.2 to 14% 3 wk after administration of a single dose of the agent, with a rapid recovery within 1 week. 10 patients given 5-day courses of DTIC at 3-wk intervals showed no decline in CMI after two courses, and 7 of the 10 had no decline even after three courses. Three of the four patients who achieved a remission lost BF previously present: BF reappeared in both patients studied during a subsequent relapse. BCG intradermally or intralesionally elevated CMI within 2 mo after initiation of therapy, but despite continuation of the injections CMI returned to base line in all but two of the nine patients studied. These results indicate that chemotherapy for melanoma with nitrosoureas or DTIC at these schedules is not profoundly immunosuppressive towards tumor-specific immunity, as measured by our procedures. Putative immunotherapy with BCG at these schedules was likewise only transiently stimulatory.
D000328:Adult; D000961:Antilymphocyte Serum; D001500:BCG Vaccine / Q000627:therapeutic use*; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods; D003606:Dacarbazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007166:Immunosuppressive Agents; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D013329:Structure-Activity Relationship; D014226:Triazenes / Q000627:therapeutic use*
D000961:Antilymphocyte Serum; D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D009607:Nitrosourea Compounds; D014226:Triazenes; D003606:Dacarbazine